Treatment and diagnosis of erectile dysfunction.
Inject into the dorso-lateral aspect of the proximal third of penis, avoid visible veins; rotate inj side and site. Determine optimum dose in office. If no response, may give 2nd dose after 1 hr; if partial response occurs, wait 24 hrs before next dose. Vasculogenic, psychogenic, or mixed etiology: initially 2.5mcg; if partial response, may give 2nd dose of 5mcg; may increase in increments of 5–10mcg until desired response. If no response to 1st dose, may give 2nd dose of 7.5mcg; may increase in increments of 5–10mcg until desired response. Neurogenic etiology: initially 1.25mcg; may give 2nd dose of 2.5mcg, and 3rd dose of 5mcg; may increase in increments of 5mcg until desired response. Usual max: 60mcg and 3 inj/week; allow at least 24 hrs between doses. Reduce dose if erection lasts over 1 hr.
Not recommended; see Contraindications.
Predisposition to priapism. Anatomical penile deformation. Penile implants. Patients for whom sexual activity is inadvisable or contraindicated. Women. Children. Newborns.
Treat priapism immediately. Patient must not adjust dose on own. Reevaluate every 3 months. Discontinue if penile fibrosis occurs.
Concomitant vasoactive agents: not recommended. Caution with anticoagulants.
Priapism, prolonged erection, penile pain or fibrosis, inj site hematoma or ecchymosis, prostatic disorder, penile rash or edema, other local effects, hypertension, headache, increased risk of blood-borne diseases, others.
Vials (10, 20, or 40mcg)—6
Kits (5, 10, or 20mcg vials + diluent syringes)—6
Ampules (10, 20, or 40mcg)—5
Caverject impulse (10 or 20mcg dual chamber syringe systems + supplies)—2